Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

Edward Ayoub, David Lehotzky, Li Li, Muharrem Muftuoglu, Yuki Nishida, Vakul Mohanty, Jake S Leighton, Tallie Patsilevas, Mahesh Basyal, Andrea Bedoy, Torsten Haferlach, Koichi Takahashi, Ken Chen, Nicholas Navin, Ghayas C. Issa, Gad Getz, Michael Andreeff

Blood (2024) 144 (Supplement 1): 61.

https://doi.org/10.1182/blood-2024-211845

Published: 2024

Journal Articles

“Guided” Unsupervised Multiplexed Cytof Analysis Enhances Detection of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Muharrem Muftuoglu, Li Li, Mahesh Basyal, Jiangxing Lv, Yukun Tan, Ken Chen, Michael Andreeff

Blood (2024) 144 (Supplement 1): 6178.

https://doi.org/10.1182/blood-2024-212260

Published: 2024

Journal Articles

Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Rasoul Pourebrahim, Priyanka Khanna, Dexin Yang, Muharrem Muftuoglu, Lauren B. Ostermann, Shayaun Khazaei, Ran Zhao, Amma Asare, Richard A. Hajek, Sanghoon Lee, Sara Corvingo, Mihai Gagea, Anil Sood, Ruoyan Li, Koichi Takahashi, Michael Andreeff

Blood (2024) 144 (Supplement 1): 726.

https://doi.org/10.1182/blood-2024-208373

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2024) 144 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2024-204296

Published: 2024

Journal Articles

TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Li Li, Muharrem Muftuoglu, Edward Ayoub, Aram Bidikian, Prashant Menon, Jiangxing Lv, Mahesh Basyal, Andrea Bedoy, Anudishi Tyagi, Amanda Eckstrom, Venkata Lokesh Battula, Navin Varadarajan, Ghayas C. Issa, Michael Andreeff

Blood (2024) 144 (Supplement 1): 330.

https://doi.org/10.1182/blood-2024-210412

Published: 2024

Journal Articles

Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms

Rasoul Pourebrahim, Dexin Yang, Priyanka Khanna, Muharrem Muftuoglu, Lauren B. Ostermann, Shayaun Khazaei, Ran Zhao, Mihai Gagea, Simona Colla, Guillermo Garcia-Manero, Ruoyan Li, Michael Andreeff, Koichi Takahashi

Blood (2024) 144 (Supplement 1): 882.

https://doi.org/10.1182/blood-2024-207582

Published: 2024

Journal Articles

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Blood (2023) 142 (Supplement 1): 158.

https://doi.org/10.1182/blood-2023-186699

Published: 2023

Journal Articles

Single-Cell Genomics and Proteomics Reveals Venetoclax-Resistant Monocytic Differentiation of TP53 LOH Clones in TP53 Mutant AML

Edward Ayoub, Li Li, Muharrem Muftuoglu, Yuki Nishida, Vakul Mohanty, Jake S Leighton, Tallie Patsilevas, Mahesh Basyal, Andrea Bedoy, Torsten Haferlach, Koichi Takahashi, Ken Chen, Nicholas Navin, Ghayas C. Issa, Michael Andreeff

Blood (2023) 142 (Supplement 1): 5014.

https://doi.org/10.1182/blood-2023-187121

Published: 2023

Journal Articles

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Xiaoli Wang, Andrew Davis, Xiaoping Su, Muharrem Muftuoglu, Cecile Krejsa, John Mascarenhas, Michael Andreeff, Ronald Hoffman

Blood (2023) 142 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2023-187426

Published: 2023

Journal Articles

Single-Cell Proteomic Analysis Reveals Menin Inhibition-Induced Proteomic Alterations in AML Patients Treated with Revumenib

Muharrem Muftuoglu, Li Li, Mahesh Basyal, Edward Ayoub, Jiangxing Lv, Andrea Bedoy, Tallie Patsilevas, Aram Bidikian, Ghayas C. Issa, Michael Andreeff

Blood (2023) 142 (Supplement 1): 2933.

https://doi.org/10.1182/blood-2023-191216

Published: 2023

Journal Articles

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

Muharrem Muftuoglu, Mahesh Basyal, Li Li, Jiangxing Lv, Lauren B. Ostermann, Ran Zhao, Baozhen Ke, Hiroki Akiyama, Po Yee Mak, Bing Z. Carter, Han Deng, Yongshuai Li, Brian S. Garrison, Kanya L. Rajangam, Michael Andreeff

Blood (2023) 142 (Supplement 1): 4831.

https://doi.org/10.1182/blood-2023-191127

Published: 2023

Journal Articles

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

Blood (2023) 142 (Supplement 1): 3264.

https://doi.org/10.1182/blood-2023-190712

Published: 2023

Journal Articles

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission

Priyanka Sharma, Lauren B. Ostermann, Sujan Piya, Baozhen Ke, Natalia Baran, Anudishi Tyagi, Muharrem Muftuoglu, Mahesh Basyal, Qi Zhang, Joanne Munck, Kim-Hien Dao, Martin Sims, Bing Z. Carter, Venkata Lokesh Battula, Michael Andreeff, Gautam Borthakur

Blood (2023) 142 (Supplement 1): 412.

https://doi.org/10.1182/blood-2023-185700

Published: 2023

Journal Articles

Age-Specific Induction of Mutant p53 Drives Clonal Hematopoiesis in Adult Mice Leading to Acute Myeloid Leukemia

Rasoul Pourebrahim, Shayaun Khazaei, Lauren B. Ostermann, Ran Zhao, Muharrem Muftuoglu, Michael Andreeff

Blood (2023) 142 (Supplement 1): 1382.

https://doi.org/10.1182/blood-2023-186454

Published: 2023

Journal Articles

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Abhishek Maiti, Muharrem Muftuoglu, James J. Ignatz-Hoover, Courtney D. DiNardo, Farhad Ravandi, Michael Andreeff, Lianchun Xiao, Xuelin Huang, Keyur P. Patel, Jason B Litten, Eliot Bourk, Stephanie Astrow, Hagop M. Kantarjian, Ben K. Tomlinson, Naval Daver, David Wald

Blood (2023) 142 (Supplement 1): 4863.

https://doi.org/10.1182/blood-2023-182885

Published: 2023

Journal Articles

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Blood (2023) 142 (12): 1056–1070.

https://doi.org/10.1182/blood.2022019047

Published: 2023

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Blood (2022) 140 (Supplement 1): 6206–6208.

https://doi.org/10.1182/blood-2022-165359

Published: 2022

Journal Articles

Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

Priyanka Sharma, Sujan Piya, Natalia Baran, Muharrem Muftuoglu, Mahesh Basyal, Vivian Ruvolo, Christopher J. Hindley, Kim-Hien Dao, Martin Sims, Michael Andreeff, Gautam Borthakur

Blood (2022) 140 (Supplement 1): 3093–3094.

https://doi.org/10.1182/blood-2022-165552

Published: 2022

Journal Articles

Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax

Muharrem Muftuoglu, Musa Yilmaz, Mahesh Basyal, Li Li, Takahiko Seki, Arnaud Lesegretain, Naval Daver, Michael Andreeff

Blood (2022) 140 (Supplement 1): 2273–2274.

https://doi.org/10.1182/blood-2022-171124

Published: 2022

Journal Articles

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Yuki Nishida, Jo Ishizawa, Edward Ayoub, Tallie Patsilevas, Lauren Ostermann, Rafael Heinz Montoya, Muharrem Muftuoglu, Vivian Ruvolo, Po Yee Mak, Wenjing Tao, Bing Z Carter, Kensuke Kojima, Naval Daver, Arnaud Lesegretain, Takahiko Seki, Sharon Shacham, Marina Konopleva, Michael Andreeff

Blood (2021) 138 (Supplement 1): 505.

https://doi.org/10.1182/blood-2021-149260

Published: 2021

NARROW

Single-Cell Multiomics Unveils Venetoclax-Resistant Monocytic Differentiation and Immune Evasion in TP53 Mutant AML Clones

“Guided” Unsupervised Multiplexed Cytof Analysis Enhances Detection of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Mitigating Therapy-Related Myeloid Neoplasia in p53-Mutant Clones through Targeted DNA Repair Pathway Inhibition with PARP Inhibitors

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

TP53 Mutations within T Cells Induce T-Cell Exhaustion and Functional Impairment in TP53 Mutant AML

Novel p53 Mutant Mouse Model Recapitulates the Biology of Human Therapy-Related Myeloid Neoplasms

Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML

Single-Cell Genomics and Proteomics Reveals Venetoclax-Resistant Monocytic Differentiation of TP53 LOH Clones in TP53 Mutant AML

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

Single-Cell Proteomic Analysis Reveals Menin Inhibition-Induced Proteomic Alterations in AML Patients Treated with Revumenib

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

CLL Cell-Derived Exosomes Impair Immune Function and Normal Hematopoiesis in CLL

ERK1/2 Inhibition Overcomes Resistance to Venetoclax in AML By Inhibiting Drp1 Dependent Mitochondrial Fission

Age-Specific Induction of Mutant p53 Drives Clonal Hematopoiesis in Adult Mice Leading to Acute Myeloid Leukemia

Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase Ib Trial

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Inhibition of ERK1/2 Reverses Venetoclax-Induced Autophagy to Overcome Resistance in Acute Myeloid Leukemia

Single-Cell Proteomic Interrogation of FLT3-ITD Leukemia Compartment Revealsdistinct Leukemia Cell Populations Resistant to Quizartinib, Decitabine and Venetoclax

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only